Literature DB >> 10094680

Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Y Zhang1, A Scorpio, H Nikaido, Z Sun.   

Abstract

Pyrazinamide (PZA) is an important antituberculosis drug. Unlike most antibacterial agents, PZA, despite its remarkable in vivo activity, has no activity against Mycobacterium tuberculosis in vitro except at an acidic pH. M. tuberculosis is uniquely susceptible to PZA, but other mycobacteria as well as nonmycobacteria are intrinsically resistant. The role of acidic pH in PZA action and the basis for the unique PZA susceptibility of M. tuberculosis are unknown. We found that in M. tuberculosis, acidic pH enhanced the intracellular accumulation of pyrazinoic acid (POA), the active derivative of PZA, after conversion of PZA by pyrazinamidase. In contrast, at neutral or alkaline pH, POA was mainly found outside M. tuberculosis cells. PZA-resistant M. tuberculosis complex organisms did not convert PZA into POA. Unlike M. tuberculosis, intrinsically PZA-resistant M. smegmatis converted PZA into POA, but it did not accumulate POA even at an acidic pH, due to a very active POA efflux mechanism. We propose that a deficient POA efflux mechanism underlies the unique susceptibility of M. tuberculosis to PZA and that the natural PZA resistance of M. smegmatis is due to a highly active efflux pump. These findings may have implications with regard to the design of new antimycobacterial drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094680      PMCID: PMC93615     

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  28 in total

1.  Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system.

Authors:  A A Neyfakh; V E Bidnenko; L B Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  The effect of nicotinic acid amide on experimental tuberculosis of white mice.

Authors:  D McKENZIE; L MALONE
Journal:  J Lab Clin Med       Date:  1948-10

3.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

4.  Radioactive content of Mycobacterium tuberculosis after exposure to 14C-isoniazid.

Authors:  J Youatt; S H Tham
Journal:  Am Rev Respir Dis       Date:  1969-07

Review 5.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples.

Authors:  H Nikaido; D G Thanassi
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

7.  Basis for lack of drug susceptibility of atypical mycobacteria.

Authors:  H L David
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

8.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin.

Authors:  X Z Li; D M Livermore; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

10.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

View more
  98 in total

1.  Spent culture supernatant of Mycobacterium tuberculosis H37Ra improves viability of aged cultures of this strain and allows small inocula to initiate growth.

Authors:  Z Sun; Y Zhang
Journal:  J Bacteriol       Date:  1999-12       Impact factor: 3.490

2.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

4.  Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Niuris C Mirabal; Sergio L Yzquierdo; Dihadenys Lemus; Mariela Madruga; Yoslaine Milián; Miguel Echemendía; Howard Takiff; Anandi Martin; Patrick Van der Stuyf; Juan Carlos Palomino; Ernesto Montoro
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

5.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

6.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

7.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil.

Authors:  Vívian de F Sumnienski Rodrigues; Maria Alice Telles; Marta Osório Ribeiro; Patrícia Izquierdo Cafrune; Maria Lucia Rosa Rossetti; Arnaldo Zaha
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

8.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

9.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

10.  Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.

Authors:  Takemasa Takii; Yoshifumi Yamamoto; Taku Chiba; Chiyoji Abe; John T Belisle; Patrick J Brennan; Kikuo Onozaki
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.